Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors

We tested the antitumor efficacy of mTOR catalytic site inhibitor MLN0128 in models with intrinsic or acquired rapamycin-resistance. Cell lines that were intrinsically rapamycin-resistant as well as those that were intrinsically rapamycinsensitive were sensitive to MLN0128 in vitro. MLN0128 inhibite...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Hassan, Burhan, Akcakanat, Argun, Sangai, Takafumi, Evans, Kurt W., Adkins, Farrell, Eterovic, Agda Karina, Zhao, Hao, Chen, Ken, Chen, Huiqin, Do, Kim-Anh, Xie, Shelly M., Holder, Ashley M., Naing, Aung, Mills, Gordon B., Meric-Bernstam, Funda
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2014
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226703/
https://ncbi.nlm.nih.gov/pubmed/25261369
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы